Should all patients with an acute myocardial infarction be referred for direct PTCA?

Peter P de Jaegere, Patrick W Serruys and Maarten L Simoons

*Heart* 2004;90;1352-1357
doi:10.1136/hrt.2003.019091

Updated information and services can be found at:
http://heart.bmjjournals.com/cgi/content/full/90/11/1352

These include:

**Data supplement**
"Web-only References"
http://heart.bmjjournals.com/cgi/content/full/90/11/1352/DC1

**References**
This article cites 20 articles, 15 of which can be accessed free at:
http://heart.bmjjournals.com/cgi/content/full/90/11/1352#BIBL

**Rapid responses**
You can respond to this article at:
http://heart.bmjjournals.com/cgi/eletter-submit/90/11/1352

**Email alerting service**
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

**Topic collections**
Articles on similar topics can be found in the following collections

- Heart Education (249 articles)
- Acute coronary syndromes (17 articles)
- Ischemic heart disease (2059 articles)
- Vascular Surgery (333 articles)

**Notes**

To order reprints of this article go to:
http://www.bmjjournals.com/cgi/reprintform

To subscribe to *Heart* go to:
http://www.bmjjournals.com/subscriptions/
Coronary disease

SHOULD ALL PATIENTS WITH AN ACUTE MYOCARDIAL INFARCTION BE REFERRED FOR DIRECT PTCA?

Peter P de Jaegere, Patrick W Serruys, Maarten L Simoons


SCOPE OF THE PROBLEM

Acute myocardial infarction (AMI) is a frequent clinical condition associated with a high immediate and short term mortality and long term morbidity. The pre-hospital case fatality rate is approximately 32%, and is most often caused by malignant arrhythmias.1 In-hospital mortality of those patients who reach the hospital alive is 8–15%.1 In case of survival, the patient may become severely incapacitated because of heart failure as a result of the loss of normal functioning myocardium and ventricular remodelling.2

In almost all patients, AMI is caused by an acute thrombotic coronary occlusion following the rupture of the cap of an atherosclerotic plaque.3 The associated ischaemic injury and subsequent myocardial necrosis spreads from the subendocardial to the subepicardial myocardium in a time span of several hours.4 Irreversible loss of subendocardial cardiomyocytes occurs after 30 minutes while subepicardial cardiomyocytes may survive for up to six hours. Therefore, to save the patient from sudden death and to save the ventricle, thus preventing heart failure, early diagnosis and treatment are imperative.

Myocardial salvage depends on the prompt, complete, and sustained restoration of myocardial perfusion. At present, this can only be obtained by re-establishing coronary flow, although coronary reperfusion does not necessarily imply myocardial perfusion.5 In practice, the choice between thrombolysis and PTCA depends on, among others, physician preferences, availability of infrastructure, economic factors, and time of admission, rather than clinical evidence.1

THE CASE FOR THROMBOLYTIC TREATMENT

A vast number of trials have consistently and unequivocally proven that thrombolysis reduces infarct size and mortality and improves long term outcome.1 The benefit of treatment is observed in patients with different levels of risk. Patients who present early and who receive treatment within two hours after onset of symptoms benefit the most (fig 1).3 4 Thrombolytic drugs can now be administrated by a single bolus; thus, this approach is applicable in almost all circumstances and can be started in the very early phase of AMI, even before hospital admission. Pre-hospital initiation of treatment may save one hour in comparison to the in-hospital administration and is associated with a fourfold higher incidence of aborted infarction (17.1% v 4.5%) and an absolute reduction of 2.0% (relative 17%) in hospital mortality.5 On-site initiation of treatment is the unsurpassed opportunity of early management since public education has failed to make patients seek help earlier.8

Thrombolysis, nonetheless, has a number of limitations that affects its application and efficacy. It fails to induce complete restoration of coronary flow (TIMI (thrombolysis in myocardial infarction) grade 3) in 30–40% of the patients, and early reocclusion occurs in 5–6% of the patients.9 Because of the inherent risk of bleeding, thrombolysis cannot be used in patients with bleeding disorders, those receiving anticoagulant drugs, or patients who have undergone recent surgery or trauma. Intracranial haemorrhage is the most extreme complication. It occurs in approximately 1% of patients but may exceed 2% depending on the number of risk factors present.10 Thrombolysis does not resolve the underlying plaque and stenosis. The residual
stenosis may cause ischaemia that may hamper ventricular recovery. These limitations have stimulated the (re)appraisal of mechanical reperfusion.

WHY DIRECT OR PRIMARY PTCA?

The first comparisons of PTCA without previous or concomitant thrombolytic treatment (direct or primary PTCA) with in-hospital thrombolysis revealed that direct PTCA is associated with a higher proportion of patients reaching TIMI 3 flow (90%), and a better left ventricular function, lower incidence of mortality, reinfarction, stroke, recurrent ischaemia, and bleeding complications. Analysis of 23 randomised studies confirmed the superiority of direct PTCA in the reduction of death, reinfarction, and stroke at 30 days, even when the patient is transferred from one hospital to the other (table 1). As a result, direct PTCA became embraced as the first choice treatment of AMI. It is in line with the proposal of the National Heart Attack Alert Program to send patients with an AMI to a PTCA centre, similar to trauma patients, and not to the nearest hospital. However, the opinion of the NRMI investigators who found a similar in-hospital and 90 day mortality rate in more than 305 000 patients, irrespective of the admission to a community or tertiary referral center (table 2). They proposed to treat patients with AMI at the closest medical facility, rather than sending them to a regional centre with specialised facilities.

ARGUMENTS IN FAVOUR FOR REFERRING EVERY PATIENT FOR DIRECT PTCA

The strongest argument for referring every patient for direct PTCA is the better clinical outcome after direct PTCA (table 1). An even better outcome after PTCA may have occurred in these studies if state of the art PTCA techniques had been used. Stents were used to a varying degree in only 50% of the studies and a glycoprotein IIb/IIIa receptor blocker in only 25%, despite the superiority of stents over balloon angioplasty to prevent restenosis, and the recognised value of glycoprotein IIb/IIIa receptor blockers to prevent thrombotic complications. This contrasts with the use of the most powerful thrombolytic drug in patients assigned to thrombolysis. Accelerated tissue plasminogen activator (acc t-PA), which is associated with a higher TIMI 3 rate and survival benefit than streptokinase, was used in most of the studies and patients (69%). Note is the superiority of PTCA when patients were transported from a community hospital to a PTCA centre, despite a delay in the onset of treatment of approximately 40 minutes (tables 3 and 4).

Similarly, the outcome in the thrombolytic treated patients may have been better with a more liberal use of rescue PTCA. Rescue PTCA was applied in a minority of the patients, except for those in the CAPTIM study (tables 3 and 4). The role of systematic PTCA rather than rescue PTCA is unclear. The first randomised studies failed to show an additional benefit of

### Table 1 Short term clinical outcome after direct PTCA and thrombolytic treatment

<table>
<thead>
<tr>
<th></th>
<th>PTCA</th>
<th>Thrombolysis</th>
<th>Odds ratio (95% CI)</th>
<th>Absolute risk difference</th>
<th>Number to treat</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients [n]</td>
<td>3717</td>
<td>3720</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Death</td>
<td>5.0</td>
<td>7.0</td>
<td>0.70 (0.6 to 0.9)</td>
<td>2.0</td>
<td>50</td>
</tr>
<tr>
<td>Non-fatal reinfarction</td>
<td>3.0</td>
<td>7.0</td>
<td>0.35 (0.3 to 0.5)</td>
<td>4.0</td>
<td>25</td>
</tr>
<tr>
<td>Stroke</td>
<td>1.0</td>
<td>2.0</td>
<td>0.46 (0.3 to 0.7)</td>
<td>1.0</td>
<td>100</td>
</tr>
<tr>
<td>Intracranial haemorrhage</td>
<td>0.05</td>
<td>1.0</td>
<td>0.05 (0.006 to 0.35)</td>
<td>0.95</td>
<td>105</td>
</tr>
<tr>
<td>Composite</td>
<td>8.0</td>
<td>14.0</td>
<td>0.5 (0.45 to 0.6)</td>
<td>6.0</td>
<td>16</td>
</tr>
</tbody>
</table>

Events are expressed in relative numbers (%). Patients with AMI complicated by cardiogenic shock are not included in this analysis. Modified from Keeley et al, with permission.

Figure 1 Left panel: Proportional 35 day mortality reduction is highest in patients treated within one hour (48%, 95% confidence interval (CI) 31% to 61%) and within two hours (44%, 95% CI 32% to 53%) versus those treated later (20%, 95% CI 15% to 25%). Right panel: Relation between absolute benefit of thrombolytic treatment and treatment delay described by a linear and a non-linear function. There is a reduction in benefit of approximately 1.6 (0.5) lives per 1000 patients per hour treatment delay. Benefit of fibrinolytic treatment was (mean (SD)) 65 (14), 37 (9), 26 (6), and 29 (5) lives saved per 1000 treated patients in the 0–1, 1–2, 2–3, and 3–6 hour intervals, respectively. Reproduced from Boersma et al. with permission.
systematic PTCA after thrombolysis, while a recent study reported a better outcome when stent implantation was performed within six hours after thrombolysis in comparison to a delayed elective intervention at two weeks.12–15

COMMENTS AND UNRESOLVED ISSUES

The patients enrolled in the randomised studies may not be representative of those seen in daily practice. In general, they have a lower baseline risk because of the inclusion and exclusion criteria (for example, eligibility for both thrombolysis and PTCA) and selection bias. The open design, physician preferences or prejudices, and logistical aspects dictated by, for example, time of presentation may explain the latter. In both the NRMI registry and the C-PORT study, most patients underwent PTCA during the office hours.21 6 The initiation of treatment takes longer during out-of-office hours, in particular for more complex treatments such as PTCA. This may affect outcome since time to treatment is a main determinant of outcome. This has been clearly established for thrombolysis (fig 1) but is less apparent in the case of PTCA. A significant added delay is less than 60–90 minutes.17 Longer delays are associated with increased mortality.17 Other data suggest that direct PTCA is superior to thrombolysis provided the added delay is less than 60–90 minutes. Other data suggest that direct PTCA is superior to thrombolysis provided the added delay is less than 60–90 minutes. Other data suggest that direct PTCA is superior to thrombolysis provided the added delay is less than 60–90 minutes. Other data suggest that direct PTCA is superior to thrombolysis provided the added delay is less than 60–90 minutes. Other data suggest that direct PTCA is superior to thrombolysis provided the added delay is less than 60–90 minutes. Other data suggest that direct PTCA is superior to thrombolysis provided the added delay is less than 60–90 minutes. Other data suggest that direct PTCA is superior to thrombolysis provided the added delay is less than 60–90 minutes. Other data suggest that direct PTCA is superior to thrombolysis provided the added delay is less than 60–90 minutes. Other data suggest that direct PTCA is superior to thrombolysis provided the added delay is less than 60–90 minutes. Other data suggest that direct PTCA is superior to thrombolysis provided the added delay is less than 60–90 minutes. Other data suggest that direct PTCA is superior to thrombolysis provided the added delay is less than 60–90 minutes. Other data suggest that direct PTCA is superior to thrombolysis provided the added delay is less than 60–90 minutes. Other data suggest that direct PTCA is superior to thrombolysis provided the added delay is less than 60–90 minutes. Other data suggest that direct PTCA is superior to thrombolysis provided the added delay is less than 60–90 minutes. Other data suggest that direct PTCA is superior to thrombolysis provided the added delay is less than 60–90 minutes. Other data suggest that direct PTCA is superior to thrombolysis provided the added delay is less than 60–90 minutes.

The incidence of mortality and reinfarction in the randomised trials is lower than in population based surveys and, despite a large relative reduction in events after direct PTCA, the absolute difference in outcome between thrombolysis and PTCA is much smaller (tables 1 and 2).12 14 The latter provides the estimate of the number of patients who need to be treated to save one from a particular event and can be used to evaluate treatment (table 1). Despite the small absolute differences, the direction of benefit for all outcome measures favours direct PTCA. This is especially true for reinfarction, which is associated with a high mortality and further deterioration of the ventricular function.

Costs and logistics need to be considered as well. The costs of direct PTCA increase considerably in hospitals without full existing resources or with a low annual caseload. In addition, a lack of infrastructure may impede delivery of care. Less than 10% and 25% of hospitals in Europe and the USA, respectively, have PTCA facilities. An acute PTCA programme implies an availability of a dedicated medical and paramedical team on a 24 hour/seven day a week basis.

Table 2  In-hospital events of patients with AMI admitted in different types of hospitals

<table>
<thead>
<tr>
<th>Study</th>
<th>Patients</th>
<th>Randomisation</th>
<th>Thrombolysis</th>
<th>PTCA</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRAGUE-2</td>
<td>ST AMI &lt;12 h</td>
<td>In community hospital without PTCA facility:</td>
<td>Streptokinase</td>
<td>Stents used in 63%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Thrombolysis or direct PTCA provided start interhospital transport possible within 30 mins and distance &lt;120 km</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DANAMI-2</td>
<td>ST AMI &lt;12 h</td>
<td>In community hospital or PTCA centre:</td>
<td>Accelerated (acc) t-PA</td>
<td>Stents used in 81% Glycoprotein IIb/IIIa blocker in 39%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Thrombolysis or direct PTCA if admitted in community hospital:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>provided transport to PTCA centre completed within 3 hours</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAPTIM</td>
<td>ST AMI &lt;6 h</td>
<td>On site to:</td>
<td>Pre-hospital acc t-PA With rescue PTCA strategy</td>
<td>Stents used in 81% Glycoprotein IIb/IIIa blocker in 39%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>thrombolysis or direct PTCA + transport to PTCA centre, provided transport duration &lt;1 hour</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Use of rescue PTCA: in DANAMI-2 study 1.9%, CAPTIM study 26%, PRAGUE-2 study 6.4%. Any PTCA at 30 days: in DANAMI-2 study 16.5%, CAPTIM study 70.4%.
Because of practical limitations, it is expected that the short door-to-balloon times reported in the randomised trials will not be repeated in the real world.\textsuperscript{69}

**A PRAGMATIC APPROACH**

There is no evidence that every patient with an evolving AMI should be referred for direct PTCA. The choice of treatment should be based upon an assessment of the baseline risk of the individual patient, and a risk/benefit evaluation of the possible treatment modalities and logistics. Some patients (the elderly, patients with antecedents of heart failure, diabetes, stroke or bypass surgery, patients with an anterior infarction and/or signs of heart failure or shock at admission) are at increased risk.\textsuperscript{6} They benefit more from direct PTCA than from thrombolytic treatment, although it should be appreciated that this information stems from post-hoc subgroup analyses.\textsuperscript{62–64}

The time interval from onset of symptoms to presentation should have a central role in the selection of treatment. None of the randomised comparisons fully took advantage of the possibility of early diagnosis and initiation of treatment on site, before transportation or admission, except for the CAPTIM study.\textsuperscript{11} Patients were randomised at the site of initial management, most often at home or the workplace, to either pre-hospital thrombolysis or transport for direct PTCA. Patients randomised to pre-hospital thrombolysis were also transported to a PTCA centre for rescue PTCA. The latter was decided upon at the discretion of the attending physician. The median time delay between onset of symptoms and initiation of treatment was 130 minutes for pre-hospital thrombolysis and 190 minutes for direct PTCA. Rescue PTCA was performed in 26% of the thrombolytic patients. At variance with all other studies, direct PTCA was not better than the pre-hospital thrombolysis strategy (tables 1 and 4).

More interestingly, a subgroup analysis disclosed a strong trend toward a lower mortality and less cardiogenic shock in patients treated with pre-hospital thrombolysis within two hours after onset of symptoms (table 5).\textsuperscript{19} In patients presenting later than two hours after onset of symptoms, there was a trend of superiority of direct PTCA.

This was also found in a subgroup analysis of the PRAGUE-2 study that revealed a similar 30 day mortality with in-hospital thrombolysis with streptokinase and direct PTCA in patients presenting within three hours (7.3% v 7.4%); however, if treated after three hours, 30 day mortality with thrombolysis rose considerably compared to PTCA (15.3% v 6.0%, respectively).\textsuperscript{7}

Such an effect was not observed in the DANAMI-2 study.\textsuperscript{16} In this study 1572 patients were randomised to direct PTCA or alteplase. In total, 1129 patients (72%) were randomised in a community hospital, and 567 were subsequently transported to a PTCA centre for direct PTCA. The median interhospital transport time was 32 minutes. No pharmacological treatment aimed at the restoration of flow was started before transport. The median door-to-balloon time of patients directly admitted to the PTCA centre was 26 minutes, while for those patients initially admitted to a community hospital it was 93 minutes. The main study finding was a 40% relative reduction in the composite outcome (30 day death, reinfarction, stroke) in patients enrolled in the community hospitals and 45% in patients enrolled in the PTCA centres in favour of direct PTCA. The benefit of direct PTCA was driven by a 75% relative reduction in reinfarction (1.6% v 6.3%), whereas there was no difference in death and stroke. At variance with the CAPTIM and PRAGUE study, direct PTCA was also superior to thrombolysis in patients admitted within two hours. This discrepancy is unclear. A subgroup effect cannot be excluded and may have biased the results. The advantage

### Table 4

**Clinical events at 30 days in studies with interhospital or direct transport of patients to a PTCA centre**

<table>
<thead>
<tr>
<th></th>
<th>PRAGUE-2</th>
<th>DANAMI-2</th>
<th>CAPTIM</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Lysis</td>
<td>PTCA</td>
<td>Lysis</td>
</tr>
<tr>
<td>Patients [n]</td>
<td>421</td>
<td>429</td>
<td>782</td>
</tr>
<tr>
<td>Death</td>
<td>10.0</td>
<td>6.2</td>
<td>7.8</td>
</tr>
<tr>
<td>Reinfarction</td>
<td>3.1</td>
<td>1.4</td>
<td>6.3</td>
</tr>
<tr>
<td>Stroke</td>
<td>2.1</td>
<td>0.2*</td>
<td>2.0</td>
</tr>
<tr>
<td>Composite</td>
<td>15.2</td>
<td>8.4*</td>
<td>13.7</td>
</tr>
<tr>
<td>Rescue PTCA</td>
<td>6.4</td>
<td></td>
<td>1.9</td>
</tr>
<tr>
<td>Any PTCA at 30 days</td>
<td>NR</td>
<td></td>
<td>16.5</td>
</tr>
</tbody>
</table>

All values are expressed as relative numbers (%).
*Outcomes which reached the level of significance.
NR, not recorded.

### Table 5

**Incidence of events after direct PTCA and thrombolytic treatment according to time between onset of symptoms and randomisation**

<table>
<thead>
<tr>
<th></th>
<th>&lt;2 hours</th>
<th>≥2 hours</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre-hospital lysis</td>
<td>Direct PTCA</td>
</tr>
<tr>
<td>Time to therapy [mins]</td>
<td>95 (40–175)</td>
<td>150 (82–260)</td>
</tr>
<tr>
<td>Death</td>
<td>2.2</td>
<td>5.7</td>
</tr>
<tr>
<td>Reinfarction</td>
<td>4.0</td>
<td>1.4</td>
</tr>
<tr>
<td>Stroke</td>
<td>1.3</td>
<td>0.0</td>
</tr>
<tr>
<td>Cardiogenic shock</td>
<td>1.3</td>
<td>5.3</td>
</tr>
</tbody>
</table>

Events are expressed in relative numbers (%), median time with interquartile range.
NS, not significant.
Modified from Steg et al,\textsuperscript{19} with permission.
of thrombolysis over direct PTCA in patients presenting and being treated early is, nonetheless, plausible. These patients have a fresh thrombus, which is easily dissolved by a thrombolytic drug, especially when administered very early.

Rather than referring every single patient with an AMI for direct PTCA, an integrated approach as proposed previously and by others appears to be more appropriate. It is based upon the assessment of: (1) time interval from onset of symptoms to presentation; (2) baseline risk derived from

---

**Figure 2** Management of patients with ST segment elevation acute myocardial infarction and presentation ≤ 6 hours. ASA, aspirin; LMWH, low molecular weight heparin; PTCA, percutaneous transluminal coronary angioplasty.

**Figure 3** Management of patients with ST segment elevation acute myocardial infarction. *Consider PTCA if on site lysis not possible.*
clinical examination and ECG; (3) risk/benefit assessment of treatment (bleeding and intracranial bleeding, in particular) and (4) availability and estimated time from presentation to PTCA which includes transportation and door-to-balloon time.

Two algorithms have been proposed (figs 2 and 3) The first uses the estimated myocardial area at risk (total ST shift and number of leads with shift) as the primary selection criterion. The other takes the time interval between symptom onset and presentation as the starting point. In both algorithms, pre-hospital thrombolysis is advocated for patients seen very early in the course of an infarct. The choice of the algorithm may depend on regional and institutional issues such as population density and geography, infrastructure, agreements with ambulance services, health insurance companies, and policymakers.

While there is consensus that thrombolysis should comprise the pre-hospital administration of the lytic drug, preferably as a single bolus, in combination with aspirin and weight adjusted low molecular weight heparin, the initial pharmacology strategy in patients referred for direct PTCA is the subject of investigation. The objective is to induce the TIMI 3 flow before the patient arrives in the catheterisation laboratory without the risk of major bleeding. Abciximab before but not at the time of PTCA has been shown to improve outcome.

### SUMMARY

All randomised comparisons have shown that direct PTCA is superior to thrombolysis in patients with AMI. Yet the choice of treatment strategy should depend on the careful evaluation of the risk/benefit of treatment. Issues unrelated to this assessment will most likely influence the selection of treatment in daily practice. Two algorithms have been proposed which differ in the primary selection or triage criterion (area at risk versus time interval). Based upon local and regional factors, one or the other may be chosen.

The role of rescue and systematic PTCA after thrombolysis needs further elucidation. At present, it cannot be proposed as a standard treatment.

---

**Authors’ affiliations**

P P de Jaegere, P W Serruyts, M L Simoons, Department of Cardiology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands

---

**REFERENCES**


2. World Health Organization MONICA project providing detailed information of case fatality rate during various phases of AMI.


4. Large US registry reporting treatment and outcome of more than 300 000 patients with AMI admitted in more than 1500 hospitals with different infrastructure.


6. Landmark review of the effect of thrombolysis in placebo controlled randomised studies with more than 1000 patients.


8. Meta-analysis of placebo controlled randomised studies underscoring the key role of time in AMI.

---

[Additional references available online at heart.bmj.com]